MedTrace Logo

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

NCT03802617 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 247

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.

Conditions

  • Uremic Pruritus

Interventions

DRUG

MR13A9

Intravenous administration

DRUG

Placebo

Intravenous administration

Sponsors & Collaborators

  • Maruishi Pharmaceutical

    collaborator INDUSTRY

  • Kissei Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Naomi Koshihara · Clinical Development Div.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-10-22
Completion
2019-10-22

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802617 on ClinicalTrials.gov